FDA Approvals

FDA Approvals

Episodes

Specialty:

All

Year:

All

EP. 1: FDA Approval for Lutathera in Neuroendocrine Tumors

January 26th 2018

EP. 2: FDA Approval of Second Dosing Schedule of Nivolumab

January 26th 2018

EP. 3: FDA Approval of Frontline Nivolumab/Ipilimumab Combo in RCC

January 26th 2018

EP. 4: FDA Approval of Durvalumab for Stage III Unresectable NSCLC

January 26th 2018

EP. 5: FDA Approval of Brentuximab Vedotin Plus AVD in Classical Hodgkin Lymphoma

January 26th 2018

EP. 6: FDA Approval of Frontline Osimertinib in Frontline EGFR-Mutant NSCLC

January 26th 2018

EP. 7: FDA Approval of Adjuvant Dabrafenib/Trametinib in BRAF+ Melanoma

January 26th 2018

EP. 8: FDA Approval of Frontline Daratumumab Plus VMP in Multiple Myeloma

January 26th 2018

Trending on OncLive

Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma

ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC

Mo-Rez Advances Into Combination Studies Following Robust Responses in Gynecologic Cancers

mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC

FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors